Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems

Abiraterone

J&J drug offers hope in advanced prostate cancer

Men with advanced prostate cancer lived nearly four months longer on a new pill from Johnson & Johnson, according to keenly awaited study data that researchers said would change clinical practice.

Abiraterone, which could reach the market next year, provides a new option for men with an aggressive type of prostate cancer.

Its… J&J drug offers hope in advanced prostate cancer   



J&J’s prostate cancer drug approved in EU

Johnson & Johnson’s prostate cancer drug Zytiga has been approved in the European Union, paving the way for the launch of a new treatment for men whose disease has progressed after chemotherapy, the company said on Wednesday.

The decision was expected after European regulators endorsed the treatment in July. J&J’s Janssen unit has European… J&J’s prostate cancer drug approved in EU   



end-stage kidney failure2 - early-stage cancer1 - nephrogenesis1 - chlamydia trachomatis2 - x chromosome1 - overweight1 - terminal hematuria1 - acidosis1 - bloody diarrhea1 - laser light1 - muscle wasting1 - klinefelter's syndrome1 - kidney masses1 - adhd1 - renal cell1 - obesity complications1 - radical nephrectomy4 - reduced potassium secretion1 - phospho-proteomics1 - prostate cancer detection1 - lund university1 - hemodialysis11 - laparoscopic operations1 - renal cells2 - high blood sugar1 - low-risk prostate cancer3 - physician1 - sexual changes1 - hlya1 - methylation1 -